Search

Your search keyword '"Butí M"' showing total 166 results

Search Constraints

Start Over You searched for: Author "Butí M" Remove constraint Author: "Butí M" Publisher elsevier b.v. Remove constraint Publisher: elsevier b.v.
166 results on '"Butí M"'

Search Results

1. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

6. SAT-256 - Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing

10. FRI-237 - HepCom: impact of co-morbidities on the final success of direct antiviral agents therapy in hepatitis C

14. FRI-153 - A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96

16. THU-285 - Efficacy and safety of the fixed-dose combination regimen of MK3 [MK-3682/grazoprevir/ruzasvir] with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)

18. THU-157 - Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network

22. PS-156 - MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

23. PS-042 - A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96

24. GS01 - Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry

25. GS06 - A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results

29. SAT-179 - Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice

32. FRI-113 - Treatment Discontinuation after HBsAg Loss is Safe in Chronic Hepatitis B Patients Treated with Nucleos/Tide Analogs: A Retrospective Multicenter Study (HEBESAS)

39. THU-056 - Decreasing the Risk of HCC in Caucasian Chronic Hepatitis B Patients under NUCS: Results of the Spanish Chronic Hepatitis B Registry (Ciberhep)

40. LBP511 - Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C Cohort

47. P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study

50. P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC)

Catalog

Books, media, physical & digital resources